FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021
GlobeNewswire - Mon Dec 15, 8:05AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug Administration ("FDA"
LPCN: 5.15 (+0.01)
Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 7:07AM CST
Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 2:30 p.m. ET.
LPCN: 5.15 (+0.01)
Lipocine Announces Management Changes
GlobeNewswire - Mon Nov 17, 7:18AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the departures of Dr. Srinivasan Venkateshwaran, Chief Technology Officer and Vice President Research & Development, effective November 14, 2014 and Mr. Gerald Simmons, Chief Business Development Officer, effective November 28, 2014. The Company has an ongoing search for a Chief Medical Officer and a Vice President of Business Development and Commercial.
LPCN: 5.15 (+0.01)
Lipocine axes two execs
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:58PM CST
LPCN: 5.15 (+0.01)
Lipocine Announces Financial and Operational Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 7:42AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well as recent operational highlights.
LPCN: 5.15 (+0.01)
Lipocine beats by $0.23
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:19AM CST
LPCN: 5.15 (+0.01)
Nasdaq stocks posting largest percentage increases
AP - Thu Oct 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TSCO: 77.80 (-0.66), SCSS: 27.19 (-0.08), XPLR: 6.60 (+0.06), LAKE: 8.94 (+0.07), LPCN: 5.15 (+0.01), LAWS: 25.00 (+0.61), VICR: 12.66 (+0.10), EGHT: 9.19 (-0.03), INFN: 15.22 (+0.05)
Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111
GlobeNewswire - Mon Oct 13, 6:09AM CDT
Candidate For Once Daily Dosing
LPCN: 5.15 (+0.01)
IPOs and Transactions Week in Review: September 29 - October 3
PR Newswire - Mon Oct 06, 1:25PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
RCAP: 11.23 (+0.26), CPTA: 18.40 (+0.08), PTN: 0.71 (+0.04), LPCN: 5.15 (+0.01), XGTI: 0.95 (-0.04), ENRJ: 2.43 (+0.03), SINO: 1.57 (-0.04)
SOXX, XONE, LPCN, Added To Naked Short Lists Today
M2 - Mon Oct 06, 9:30AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. iShares PHLX SOX Semiconductor Sector Index Fund (NASDAQ:SOXX), (NASDAQ:XONE), (NASDAQ:LPCN). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
XONE: 15.32 (+0.25), LPCN: 5.15 (+0.01), SOXX: 94.11 (-0.62)
Nasdaq stocks posting largest volume increases
AP - Thu Sep 25, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OBCI: 4.55 (+0.03), LYTS: 6.64 (+0.08), ALCS: 0.30 (+0.01), ENVI: 1.34 (+0.06), JACQ: 10.21 (-0.79), LPCN: 5.15 (+0.01), FNJN: 2.46 (+0.18), RITT: 0.94 (-0.02), LAND: 9.82 (+0.01), ACOR: 39.14 (+0.74), FORD: 0.95 (+0.05)
Why Lipocine (LPCN) Stock Is Surging in Morning Trading Today
at The Street - Wed Sep 24, 8:50AM CDT
Shares of Lipocine (LPCN) soared in morning trading Wednesday after the pharmaceutical company announced positive results from its Phase 3 trial of its oral treatment LPCN 1021 for low testosterone.
LPCN: 5.15 (+0.01)
Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy
GlobeNewswire - Wed Sep 24, 7:30AM CDT
-- Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects
LPCN: 5.15 (+0.01)